In patients with Chronic Heart Failure Which Polypharmacy Pheno-groups are associated with adverse health outcomes? (Polypharmacy Pheno-groups and Heart failure outcomes)

Abstract

BackgroundPatients with heart failure are living longer with the inevitable morbidity of rising medication counts. It remains uncertain what fraction of this ensuing polypharmacy exactly predicts adverse clinical outcomes. MethodsThis prospective study examined records of patients admitted to a Weill Cornell-affiliated tertiary medical institution with a confirmed diagnosis of heart failure between January 2018 to January 2022. Each patient's medications for the past four months were tallied, and a definitional threshold of ≤4, ≥5, ≥10 medications was established. The primary outcome was all-cause mortality within the study period. ResultsOut of a total of 7354 patients included in the study, 70% were males with a median age of 59 years IQR (48 – 71). The median (IQR) age-adjusted Charlson Comorbidity Index (CCI) was 21 – 5. A total of 1475 (20%) participants died within the study period. Patient cohorts with excessive polypharmacy (≥9 medications) had the highest probability of survival up to 1.6 years compared to those with lower medication thresholds (≤4); the mortality rate decreased by 18% for patients with excessive polypharmacy [HR=0.82, 95% CI: 0.71 – 0.94]). Conversely, patients with non-heart failure-related polypharmacy had increased risks of ICU admissions (aOR=1.78, 95% CI: 1.13 – 2.70). ConclusionIn an examination of a database of patients with chronic heart failure, major non-heart failure-related polypharmacy was associated with increased risks in intensive care admissions. Excessive polypharmacy was associated with increased rates of survival.